| Current Lyme ELISA tests are
short on specificity. They can generate over 20 percent false
positives. This results in either expensive and time-consuming
Western Blot confirmatory tests or potential misdiagnosis.
Immunetics’ C6 Lyme ELISA is a far more specific assay
– demonstrating 98 percent specificity in an average
population, a 10-fold improvement over current Whole Cell
Sonicate ELISAs.
Also, Immunetics’ C6 ELISA is a far more sensitive assay
– showing 97 percent sensitivity in comprehensive clinical
trials of Lyme patients at every stage of disease. The C6
test correctly detects more patients as positive than other
current methods.
Immunetics’ C6 Lyme ELISA correctly distinguishes between
true infections and vaccination response. In a study of Lyme
vaccine recipients, while current Lyme ELISAs erroneously
identified 100 percent of those vaccinated with LYMErixTM
as infected with Lyme disease, Immunetics’ C6 Lyme ELISA
correctly determined that none were infected.
And Immunetics’ C6 Lyme ELISA demonstrates superior
results across a wide range of patients in all stages of Lyme
– from early onset to late stage disseminated infection.
|
